Peter Brian Bach
#145,650
Most Influential Person Now
Peter Brian Bach's AcademicInfluence.com Rankings
Peter Brian Bachmedical Degrees
Medical
#2742
World Rank
#3175
Historical Rank
Public Health
#419
World Rank
#433
Historical Rank
Epidemiology
#518
World Rank
#540
Historical Rank

Peter Brian Bachphilosophy Degrees
Philosophy
#7827
World Rank
#11091
Historical Rank
Logic
#4861
World Rank
#6193
Historical Rank

Download Badge
Medical Philosophy
Why Is Peter Brian Bach Influential?
(Suggest an Edit or Addition)Peter Brian Bach's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population (2002) (1716)
- Benefits and harms of CT screening for lung cancer: a systematic review. (2012) (1076)
- A Paradigm Shift in U.S. Breast Reconstruction: Increasing Implant Rates (2013) (739)
- The influence of hospital volume on survival after resection for lung cancer. (2001) (678)
- Racial differences in the treatment of early-stage lung cancer. (1999) (577)
- Primary care physicians who treat blacks and whites. (2004) (573)
- Variations in lung cancer risk among smokers. (2003) (560)
- Variations in morbidity after radical prostatectomy. (2002) (542)
- Care patterns in Medicare and their implications for pay for performance. (2007) (522)
- Age and adjuvant chemotherapy use after surgery for stage III colon cancer. (2001) (510)
- Influence of hospital procedure volume on outcomes following surgery for colon cancer. (2000) (486)
- Computed tomography screening and lung cancer outcomes. (2007) (463)
- NCCN Task Force Report: Oral chemotherapy. (2008) (396)
- Survival of blacks and whites after a cancer diagnosis. (2002) (394)
- Pricing in the Market for Anticancer Drugs (2014) (384)
- Limits on Medicare's ability to control rising spending on cancer drugs. (2009) (377)
- The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma. (2004) (372)
- Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. (2013) (368)
- Hospital and Surgeon Procedure Volume as Predictors of Outcome Following Rectal Cancer Resection (2002) (342)
- Rapid-learning system for cancer care. (2010) (325)
- The Effect of Clustering of Outcomes on the Association of Procedure Volume and Surgical Outcomes (2003) (315)
- Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Summary and Appraisal of Published Evidence (2001) (296)
- Delivery of preventive services to older adults by primary care physicians. (2005) (288)
- Patient Demographic and Socioeconomic Characteristics in the SEER-Medicare Database: Applications and Limitations (2002) (273)
- Lung cancer in US women: a contemporary epidemic. (2004) (271)
- Screening for lung cancer: a review of the current literature. (2003) (259)
- Outcomes after long-term acute care. An analysis of 133 mechanically ventilated patients. (1999) (258)
- Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection (2003) (247)
- Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. (2002) (242)
- Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. (2013) (233)
- Resurrecting treatment histories of dead patients: a study design that should be laid to rest. (2004) (228)
- Primary Care Physicians' Links to Other Physicians Through Medicare Patients: The Scope of Care Coordination (2009) (223)
- Survivorship care plans in research and practice (2012) (223)
- Management of acute exacerbations of COPD: a summary and appraisal of published evidence. (2001) (223)
- Overview of the SEER-Medicare Data (2002) (188)
- The epidemiology and costs of chronic critical illness. (2002) (178)
- Clinical prediction rule for atrial fibrillation after coronary artery bypass grafting. (2004) (174)
- Components necessary for high-quality lung cancer screening: American College of Chest Physicians and American Thoracic Society Policy Statement. (2015) (169)
- Physician visits prior to treatment for clinically localized prostate cancer. (2010) (164)
- Cancer's next frontier: addressing high and increasing costs. (2010) (158)
- Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results--Medicare. (2001) (155)
- Adherence to surveillance among patients with superficial bladder cancer. (2003) (133)
- Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (2017) (132)
- FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug. (2017) (131)
- Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). (2007) (130)
- Bilateral Mastectomy versus Breast-Conserving Surgery for Early-Stage Breast Cancer: The Role of Breast Reconstruction (2015) (113)
- Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. (2013) (112)
- Pack‐years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer (2010) (112)
- The Influence of Sociodemographic Factors and Hospital Characteristics on the Method of Breast Reconstruction, Including Microsurgery: A U.S. Population–Based Study (2012) (111)
- A Decade of Mortality Reductions in Major Oncologic Surgery: The Impact of Centralization and Quality Improvement (2010) (106)
- Indication-specific pricing for cancer drugs. (2014) (105)
- Overspending driven by oversized single dose vials of cancer drugs (2016) (101)
- Identification of poor prognostic features among patients requiring mechanical ventilation after hematopoietic stem cell transplantation. (2001) (100)
- Screening for lung cancer: the guidelines. (2003) (97)
- How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement. (2010) (95)
- Hospital volume, complications, and cost of cancer surgery in the elderly. (2015) (95)
- Geographic Access and the Use of Screening Mammography (2010) (94)
- Prevalence and Risk Factors for Symptomatic Thromboembolic Events after Shoulder Arthroplasty (2006) (91)
- Risk Adjusting Survival Outcomes in Hospitals That Treat Patients With Cancer Without Information on Cancer Stage. (2015) (91)
- When the Average Applies to No One: Personalized Decision Making About Potential Benefits of Lung Cancer Screening (2012) (88)
- Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. (2005) (86)
- State expenditures for tobacco-control programs and the tobacco settlement. (2002) (81)
- The Association between Hospital Volume and Total Shoulder Arthroplasty Outcomes (2005) (73)
- Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs. (2015) (72)
- Validation of a model of lung cancer risk prediction among smokers. (2006) (71)
- A map to bad policy--hospital efficiency measures in the Dartmouth Atlas. (2010) (67)
- Translating genomics in cancer care. (2013) (66)
- Episode-based payment for cancer care: a proposed pilot for Medicare. (2011) (63)
- Predicting mortality in patients suffering from prolonged critical illness: an assessment of four severity-of-illness measures. (2001) (63)
- Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. (2013) (62)
- Fragmentation of Care for Frequently Hospitalized Urban Residents (2006) (62)
- Outcomes and resource utilization for patients with prolonged critical illness managed by university-based or community-based subspecialists. (1998) (62)
- New Math on Drug Cost-Effectiveness. (2015) (62)
- Bronchiolitis obliterans organizing pneumonia in cancer: a case series. (2002) (60)
- Is our natural-history model of lung cancer wrong? (2008) (60)
- A prognostic model for 6-month mortality in elderly survivors of critical illness. (2011) (57)
- Value-Based Pricing for Drugs: Theme and Variations. (2018) (57)
- Cost consequences of the 340B drug discount program. (2013) (56)
- Potentially Avoidable Hospitalizations for COPD and Pneumonia: The Role of Physician and Practice Characteristics (2007) (53)
- Alternative State-Level Financing for Hepatitis C Treatment-The "Netflix Model". (2018) (52)
- Gardasil: from bench, to bedside, to blunder (2010) (52)
- Comorbidities, smoking status, and life expectancy among individuals eligible for lung cancer screening (2015) (51)
- Radiation therapy facilities in the United States. (2006) (49)
- Benchmarking lung cancer mortality rates in current and former smokers. (2004) (49)
- Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending. (2017) (48)
- Risk charts: putting cancer in context. (2002) (48)
- Identifying and Measuring Hospital Characteristics Using the SEER-Medicare Data and Other Claims-Based Sources (2002) (47)
- The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities. (2014) (46)
- Physician-Driven Variation in Nonrecommended Services Among Older Adults Diagnosed With Cancer. (2016) (45)
- Overuse of health care services: when less is more … more or less. (2013) (44)
- Racial disparities and site of care. (2005) (43)
- The first months of the prescription-drug benefit--a CMS update. (2006) (43)
- Perspectives on the value of American Society of Clinical Oncology clinical guidelines as reported by oncologists and health maintenance organizations. (2003) (42)
- Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer. (2006) (41)
- Costs of cancer care: a view from the centers for Medicare and Medicaid services. (2007) (41)
- Reduced lung-cancer mortality with CT screening. (2011) (36)
- The Cost of Postoperative Pancreatic Fistula Versus the Cost of Pasireotide: Results from a Prospective Randomized Trial (2017) (36)
- High burden of palliative needs among older intensive care unit survivors transferred to post-acute care facilities. a single-center study. (2013) (35)
- Estimating individual risk for lung cancer. (2011) (31)
- Methadone dosing, heroin affordability, and the severity of addiction. (1999) (31)
- A prescription for a modern Medicare program. (2005) (30)
- Association of Hospital Costs With Complications Following Total Gastrectomy for Gastric Adenocarcinoma (2017) (30)
- Piloting IBM Watson Oncology within Memorial Sloan Kettering’s regional network. (2014) (29)
- Prescription Drugs-List Price, Net Price, and the Rebate Caught in the Middle. (2019) (27)
- Long-term central venous catheter use and risk of infection in older adults with cancer. (2014) (26)
- Federal initiatives to support rapid learning about new technologies. (2007) (25)
- Overdiagnosis in lung cancer: different perspectives, definitions, implications (2008) (23)
- Impact of Infection by Vancomycin-Resistant Enterococcus on Survival and Resource Utilization for Patients With Leukemia (2002) (23)
- Wide variation in payments for Medicare beneficiary oncology services suggests room for practice-level improvement. (2015) (22)
- Inconsistencies in findings from the early lung cancer action project studies of lung cancer screening. (2011) (22)
- ReCAP: Hospitalizations in Older Adults With Advanced Cancer: The Role of Chemotherapy. (2016) (21)
- Delays in the Publication of Important Clinical Trial Findings in Oncology (2018) (21)
- National Coverage Analysis of CAR-T Therapies - Policy, Evidence, and Payment. (2018) (21)
- Using practice guidelines to assess cancer care quality. (2005) (20)
- Medication overuse in oncology: current trends and future implications for patients and society. (2018) (20)
- Copay Assistance for Expensive Drugs: A Helping Hand That Raises Costs (2016) (17)
- Pem and the cost of multicycle maintenance. (2010) (17)
- Do the data support the comorbidity hypothesis for the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial results? (2011) (17)
- Quality of Cancer Surveillance Clinical Practice Guidelines: Specificity and Consistency of Recommendations (2017) (17)
- Changes in the availability of screening mammography, 2000–2010 (2013) (17)
- Reforming the payment system for medical oncology. (2013) (17)
- Epidemiology of lung cancer. (2000) (17)
- Consider saying yes. (2003) (17)
- Arterial Desaturation Syndrome Following Pleurodesis with Talc Slurry: Incidence, Clinical Features, and Outcome (2003) (15)
- Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir’s Value (2020) (15)
- Race, Ethnicity, Health Insurance, and Mortality in Older Survivors of Critical Illness (2017) (15)
- Payment Reform for Better Value and Medical Innovation (2017) (14)
- Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries (2021) (14)
- Low-dose CT for lung cancer screening. (2018) (14)
- Cost sharing for health care--whose skin? Which game? (2008) (13)
- Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs (2021) (13)
- Walking the Tightrope Between Treatment Efficacy and Price. (2016) (13)
- The relation between physician experience and patterns of care for patients with AIDS-related Pneumocystis carinii pneumonia: results from a survey of 1,500 physicians in the United States. (1999) (13)
- Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. (2014) (12)
- Postmenopausal hormone therapy and breast cancer: an uncertain trade-off. (2010) (12)
- Identifying Cancer-Directed Surgeries in Medicare Claims: A Validation Study Using SEER-Medicare Data. (2019) (11)
- Infused chemotherapy use in the elderly after patent expiration. (2012) (11)
- Review of Current Policy Strategies to Reduce US Cancer Drug Costs. (2019) (11)
- Critical Choices: What Information Do Patients Want When Selecting a Hospital for Cancer Surgery? (2018) (10)
- Hospital length of stay for severe COVID-19: implications for Remdesivir's value (2020) (10)
- Validity of same-side reoperation after total hip and knee arthroplasty using administrative databases. (2009) (10)
- Ramucirumab for Colon Cancer and the Problem of Rising Prices Independent of Benefits. (2015) (9)
- Outcome-blinded peer review. (2011) (9)
- Perilous potential: The chance to save lives, or lose them, through low dose computed tomography screening for lung cancer (2013) (9)
- Book Review Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care Edited by Brian D. Smedley, Adrienne Y. Stith, and Alan R. Nelson. 764 pp. Washington, D.C., National Academies Press, 2003. $79.95. 0-309-08532-2 (2003) (8)
- Female representation among US National Comprehensive Cancer Network guideline panel members. (2019) (8)
- Raising the Bar for the U.S. Preventive Services Task Force (2014) (8)
- Despite The FDA's Five-Year Plan, Black Patients Remain Inadequately Represented In Clinical Trials For Drugs. (2022) (8)
- Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer. (2017) (8)
- Mapping conflict of interests: scoping review (2021) (8)
- Cost-effectiveness analysis of an established, effective procedure. (2009) (8)
- Disenrollment from Medicare managed care among beneficiaries with and without a cancer diagnosis. (2008) (8)
- Model-Based Eligibility for Lung Cancer Screening: Where Theory Meets Practice (2018) (8)
- Computed Tomography Screening for Lung Cancer (2008) (7)
- Preventive Services Offered in Executive Physicals at Top-Ranked Hospitals. (2019) (7)
- Lung cancer screening. (2008) (7)
- Provider Differences in Use of Implanted Ports in Older Adults With Cancer (2015) (7)
- Untreated patients in "CT screening for lung cancer: update 2007". (2008) (7)
- Smoking as a factor in causing lung cancer. (2009) (7)
- Next steps for IBM Watson Oncology: Scalability to additional malignancies. (2014) (7)
- The 6 Functions of Health Insurance. (2019) (7)
- Understanding the Rewards of Successful Drug Development - Thinking Inside the Box. (2020) (7)
- Changes in Drug List Prices and Amounts Paid by Patients and Insurers (2020) (7)
- Quality Wrapped in Volume Inside a Hospital (2009) (6)
- An analysis of expenditures on primary care prescription drugs in the United States versus ten comparable countries. (2018) (6)
- The gender gap in critical care task force participation. (2019) (6)
- Money-Back Guarantees for Expensive Drugs: Wolf's Clothing but a Sheep Underneath (2018) (6)
- Practice-Changing Strategies to Deliver Affordable, High-Quality Cancer Care: Summary of an Institute of Medicine Workshop. (2013) (6)
- Using Nominal Group Technique to Identify Key Attributes of Oncology Treatments for a Discrete Choice Experiment (2019) (6)
- Physician's Office and Hospital Outpatient Setting in Oncology: It's About Prices, Not Use. (2017) (6)
- The Prescription Drug User Fee Act (2022) (6)
- Human papillomavirus vaccine coverage – Author's reply (2010) (5)
- Multiplicities in the assessment of multiple vitamins: is it too soon to tell men that vitamins prevent cancer? (2012) (5)
- Financial Conflicts of Interest Among Oncology Clinical Pathway Vendors (2017) (5)
- Beyond Jeopardy!: Harnessing IBM's Watson to improve oncology decision making. (2013) (5)
- Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer. (2020) (5)
- Hospital outpatient versus physician office cost for physician administered cancer drugs (2017) (5)
- Insights into the increasing costs of cancer drugs. (2019) (4)
- Cancer hospital advertising and outcomes: trust the messenger? (2019) (4)
- Complications Associated With Use of Long-Term Central Venous Catheters Among Commercially Insured Women With Breast Cancer. (2015) (4)
- Postmenopausal Hormone Therapy and Breast Cancer (2010) (4)
- Review of current literature (2005) (4)
- Outcomes after Long-Term Acute Care: An Analysis of 133 Mechanically Ventilated Patients. (1999) (4)
- The Accuracy and Usefulness of the National Comprehensive Cancer Network Evidence Blocks Affordability Rating (2020) (4)
- Association Between Quality of Care and the Sociodemographic Composition of Physicians’ Patient Panels: A Repeat Cross-Sectional Analysis (2011) (4)
- Computed Tomography Screening for Lung Cancer—Reply (2007) (4)
- Surrogate Markers and the Association of Low-Dose CT Lung Cancer Screening With Mortality (2018) (3)
- Re: All-cause mortality in randomized trials of cancer screening. (2002) (3)
- Trends in Female Representation on NCCN Guideline Panels. (2020) (3)
- The association between drug industry payments and NCCN guideline panel membership. (2020) (3)
- Visits to urologists and radiation oncologists prior to treatment decision making for clinically localized prostate cancer (LCaP) (2007) (3)
- Thirty Day Resource Utilization after Chimeric Antigen Receptor (CAR) T Cell Infusion for Hematologic Malignancies (2019) (3)
- NCCN Roundtable:Value-Based Decision-Making at the Bedside. (2015) (3)
- Assessment of variation in 30‐day mortality following cancer surgeries among older adults across US hospitals (2020) (3)
- Practice Patterns for Older Adult Patients With Advanced Cancer: Physician Office Versus Hospital Outpatient Setting. (2019) (3)
- Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer. (2021) (3)
- Alternative pricing strategies for cancer drugs--reply. (2015) (3)
- CT screening for lung cancer. (2007) (3)
- Which Drug Prices Should Medicare Negotiate? A "Too Little" or "Too Late" Approach. (2019) (3)
- Response to "CT screening for lung cancer: update 2007". (2008) (3)
- Expansion of the Medicare 340B Payment Program: Hospital Participation, Prescribing Patterns and Reimbursement, and Legal Challenges. (2018) (2)
- Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines. (2021) (2)
- Use of PET Imaging: Another Non-Biological Source of Racial Disparities in US Cancer Care. (2020) (2)
- Identifying providers of care to individuals with human immunodeficiency virus for a mail survey using a prescription tracking database. (1999) (2)
- Computed Tomography Screening for Lung Cancer (2013) (2)
- Assessing whether cancer stage is needed to evaluate measures of hospital surgical performance. (2019) (2)
- Re: Risk Charts: Putting Cancer in Context (2002) (2)
- Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines. (2021) (2)
- Association Between Clinical Value and Financial Cost of Cancer Treatments: A Cross-Sectional Analysis. (2020) (2)
- Improving quality and addressing the rising costs of cancer care: two birds, one stone. (2011) (2)
- Increasing Financial Payments From Industry to Medical Oncologists in the United States, 2014-2017. (2021) (2)
- Lung Cancer Screening Guidelines Updated (2012) (2)
- The impact of chemotherapy on hospitalizations and emergency care in older adults with advanced cancer. (2015) (2)
- Do surgical quality gaps cause healthcare disparities? (2008) (2)
- Predictors Of 6 Month Mortality For Elderly Survivors Of Critical Illness (2012) (1)
- JAMA Peer Reviewers in 2019. (2020) (1)
- The value of cancer treatments: Patient and clinician perspectives. (2017) (1)
- Visions of hope in cancer: focus on infrastructure: comment on "characteristics of oncology clinical trials" and "toward accountable cancer care". (2013) (1)
- Identifying Attributes of Cancer Treatments: What Do Stakeholders Consider Important? (2017) (1)
- Impact of Routine Radiographic Surveillance After Complete Resection of Lung Cance (2003) (1)
- Reviewers for the Journal, January-June 2016. (2016) (1)
- Should the American Society of Clinical Oncology Ask for Peer Review Before Publishing Its Advocacy Research? (2016) (1)
- Infused chemotherapy use in the elderly after patent expiration. (2012) (1)
- Computed Tomographic Screening for Lung Cancer—Reply (2012) (1)
- JAMA Peer Reviewers in 2020. (2021) (1)
- Evaluation of Use of Shorter Radiation Regimens for Breast and Prostate Cancer in the US, 2015-2017 (2020) (1)
- Real-world effectiveness of approved anticancer agents among Medicare beneficiaries. (2019) (1)
- Enhancing the Value of the ASCO Value Framework (2018) (1)
- Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation (2022) (1)
- Health Returns to Pharmaceutical Innovation in the Market for Oral Chemotherapy in Response to Insurance Coverage Expansion (2017) (1)
- JAMA Peer Reviewers in 2018. (2019) (1)
- The correlation between clinical benefit and financial cost of cancer drugs. (2020) (1)
- Industry Payments to Physicians are Kickbacks. How Should Stakeholders Respond? (2022) (1)
- Cancer survival in the context of growing hospital participation in Medicare ACOs. (2018) (1)
- Resource Utilization Early after Chimeric Antigen Receptor (CAR) T Cell Infusion for Hematologic Malignancies (2018) (1)
- Baseline demographics and disparities in cancer registration trials: An analysis of U.S. Food and Drug Administration approved drugs in 2015 and 2016. (2018) (1)
- Resurrecting treatment histories of dead patients. Authors' reply (2005) (1)
- Estimating hospitals’ all-payer volume of cancer surgeries from Fee-for-Service Medicare claims (2020) (1)
- Commentary on Hsiue et al: Cost savings and data limitations of new cancer drug studies (2020) (1)
- 1079-81 Preoperative risk factors for post-coronary artery bypass graft atrial fibrillation (2004) (1)
- Pharmaceutical industry payments to physicians for the promotion of cancer drugs. (2022) (0)
- Use of bone modifying agents for metastatic castrate-resistant prostate cancer. (2022) (0)
- Financial payments from the pharmaceutical industry to U.S. cancer centers, 2014-2019. (2022) (0)
- Long-term central venous catheters and infections in older adults with cancer. (2013) (0)
- Physician-driven variation in non-recommended imaging for women with early stage breast cancer. (2015) (0)
- Disenrollment from Medicare managed care: Does a cancer diagnosis make a difference? (2008) (0)
- Improving outpatient oncology practice: several steps into a long journey. (2014) (0)
- Financial conflicts of interest at three prominent oncology clinical pathway vendors. (2017) (0)
- Survival in women after diagnosis of lung cancer. (2007) (0)
- Ms. Thompson's murmur. (1992) (0)
- Thanks to reviewers in 2010 (2010) (0)
- Review of current literature (1903) (0)
- Outcomes for patients with advanced epithelial ovarian cancer treated with adjuvant chemotherapy at a regional network facility compared to the central campus (2015) (0)
- JAMA Peer Reviewers in 2004 (2016) (0)
- JAMA Internal Medicine Peer Reviewers in 2017. (2018) (0)
- High hospital volume is associated with more consistent long-term mortality rates (2021) (0)
- CT screening for lung cancer. (2007) (0)
- Use of bone modifying agents in patients with metastatic castrate-sensitive prostate cancer. (2021) (0)
- Linking Drug Costs to Their Benefits: Value-Based Drug Pricing (2017) (0)
- Thanks to Reviewers2017 (2017) (0)
- JAMA Peer Reviewers in 2018. (2019) (0)
- Opportunity for performance measurement: 30-day mortality following cancer surgeries across U.S. hospitals. (2019) (0)
- JAMA Peer Reviewers for 2003 (2017) (0)
- and Mortality in Postmenopausal Women Estrogen Plus Progestin and Breast Cancer Incidence (2010) (0)
- Definition of a Beneficial Screening Test (2009) (0)
- Slide Presentations: Sunday, October 23, 2011 | October 2011A Prognostic Model for 6-Month Mortality in Elderly Survivors of Critical Illness (2011) (0)
- PCN404 HOW DO NEW ONCOLOGY VALUE ASSESSMENT FRAMEWORKS COMPARE TO THE QALY? (2019) (0)
- Compulsory Licensing of Pharmaceuticals in High-Income Countries: A Comparative Analysis. (2022) (0)
- Lung Cancer Screening: Response (2013) (0)
- Review of current literature (1934) (0)
- Thanks to authors and peer reviewers (2007) (0)
- Reviewers for the Journal, July-December 2017. (2019) (0)
- Distribution of Predictable Risk for Lung Cancer: Use of a Lung Cancer Prediction Too (2003) (0)
- Commentary: Medicare's 2006 Oncology Demonstration Project: Lost in Translation? (2010) (0)
- Perspectives o n t he V alue o f A merican S ociety o f C linical Oncology C linical G uidelines a s R eported b y O ncologists a nd Health M aintenance O rganizations (2003) (0)
- Defining Value-Based Pricing of Drugs-Reply. (2018) (0)
- A conundrum in cancer quality measurement: Performance on long-term survival reflects performance a long time ago. (2019) (0)
- Computed tomography screening for lung cancer. Authors' reply (2007) (0)
- Global Reimbursement: The Authors Reply (2011) (0)
- But Will They Trade Health? Developing An Economic Value Framework for Oncology (2017) (0)
- Medicare Drug Benefit: A Beneficial Side Effect of the Medicare Drug Benefit (2005) (0)
- CR4 RESOURCE UTILIZATION WITHIN 30 DAYS OF CAR T CELLS FOR HEMATOLOGIC MALIGNANCIES (2019) (0)
- Thanks to Reviewers2014 (2014) (0)
- Adjuvant C hemotherapy U se f or M edicare B eneficiaries With S tage I I C olon C ancer (2002) (0)
- Using Comparative Effectiveness: The Authors Reply (2011) (0)
- Will Shifts in Oncology Outpatient Points of Care Lead to More Profits or Savings (2014) (0)
- linical Prediction Rule for Atrial Fibrillation fter Coronary Artery Bypass Grafting (2016) (0)
- Physicians' experience and survival in patients with AIDS. (1996) (0)
- Perilous Potential: Screening for Lung Cancer (2014) (0)
- Long-term central venous catheter use among cancer patients in administrative claims data. (2012) (0)
- The Zigzagging zeitgeist of health services research: Rapidly changing priorities in the field. (2014) (0)
- Who G ets A djuvant T reatment f or S tage I I a nd I II R ectal Cancer? I nsight F rom S urveillance, E pidemiology, a nd E nd Results-Medicare (2001) (0)
- Use of Postoperative Radiotherapy (PORT) for Resectable Non-Small Cell Lung Cancer (NSCLC) (2005) (0)
- Provider volume and guideline compliance in ovarian cancer patients receiving front-line chemotherapy (2018) (0)
- Thanks to Reviewers—2020 (2020) (0)
- Review of current literature (1903) (0)
- Resurrecting Treatment Histories of Dead Patients—Reply (2005) (0)
- Addressing Challenges in Lung Cancer Screening (2013) (0)
- Identifying sexual orientation in the medical record: A first step towards understanding gynecologic cancer disparities. (2018) (0)
- Ethical and human subject burdens of trials conducted to evaluate biosimilars (2021) (0)
- Adjuvant Anthracyclines and Taxanes: Quantifying the Costs of Therapeutic Advances in Breast Cancer (2009) (0)
- Response: Re: Inconsistencies in Findings from the Early Lung Cancer Action Project Studies of Lung Cancer Screening (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Peter Brian Bach?
Peter Brian Bach is affiliated with the following schools: